[go: up one dir, main page]

AR053272A1 - Determinacion de responsivos a la quimioterapia - Google Patents

Determinacion de responsivos a la quimioterapia

Info

Publication number
AR053272A1
AR053272A1 ARP060101849A ARP060101849A AR053272A1 AR 053272 A1 AR053272 A1 AR 053272A1 AR P060101849 A ARP060101849 A AR P060101849A AR P060101849 A ARP060101849 A AR P060101849A AR 053272 A1 AR053272 A1 AR 053272A1
Authority
AR
Argentina
Prior art keywords
phosphorylated
protein
refers
biological sample
cancer cells
Prior art date
Application number
ARP060101849A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR053272A1 publication Critical patent/AR053272A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G01N33/575—
    • G01N33/5752—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente se refiere a un método para determinar si una muestra biologica que contiene células cancerígenas de pulmon humanas es sensible a una combinacion de un inhibidor del receptor del factor de crecimiento epidérmico y un agente quimioterapéutico mediante a determinacion de la sobreexpresion de una proteína AKT fosforilada una proteína MAPK fosforilada en la muestra biologica. La presente también se refiere a métodos para obtener un agente candidato o seleccionar una composicion para inhibir la progresion de las células cancerígenas de pulmon en un paciente en el que se utiliza una proteína AKT fosforilada o una proteína MAPK fosforilada.
ARP060101849A 2005-05-11 2006-05-09 Determinacion de responsivos a la quimioterapia AR053272A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010244 2005-05-11
EP05011070 2005-05-23

Publications (1)

Publication Number Publication Date
AR053272A1 true AR053272A1 (es) 2007-04-25

Family

ID=36733489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101849A AR053272A1 (es) 2005-05-11 2006-05-09 Determinacion de responsivos a la quimioterapia

Country Status (14)

Country Link
US (2) US7655414B2 (es)
EP (1) EP1889066A1 (es)
JP (2) JP4847518B2 (es)
KR (1) KR100962162B1 (es)
CN (1) CN102854315A (es)
AR (1) AR053272A1 (es)
AU (1) AU2006245962B8 (es)
BR (1) BRPI0609096A2 (es)
CA (1) CA2605151A1 (es)
IL (1) IL185631A (es)
MX (1) MX2007013973A (es)
NO (1) NO20074389L (es)
RU (1) RU2416096C2 (es)
WO (1) WO2006119980A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
JP4795203B2 (ja) * 2006-11-13 2011-10-19 シスメックス株式会社 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
RU2519647C2 (ru) * 2007-07-13 2014-06-20 Нестек С.А. Выбор лекарственных средств для терапии рака легких с помощью матриц на основе антител
CN101778954A (zh) * 2007-08-14 2010-07-14 霍夫曼-拉罗奇有限公司 Egfr抑制剂治疗的预测性标记物
CN101784674A (zh) * 2007-08-14 2010-07-21 霍夫曼-拉罗奇有限公司 Egfr抑制剂治疗的预测性标记物
BRPI0817361A2 (pt) * 2007-08-14 2015-03-31 Hoffmann La Roche Marcador preditivo para tratamento com inibidor de egfr
US8187800B2 (en) 2007-10-15 2012-05-29 Precision Therapeutics, Inc. Methods for selecting active agents for cancer treatment
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
EP2250498B1 (en) 2008-02-25 2012-10-31 Prometheus Laboratories Inc. Drug selection for breast cancer therapy using antibody-based arrays
US20110059464A1 (en) * 2008-04-08 2011-03-10 Muraca Patrick J Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
WO2009140508A2 (en) * 2008-05-14 2009-11-19 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
EP2304439A4 (en) * 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
US20110306514A1 (en) 2009-01-14 2011-12-15 United States Department of Health and Human Services Ratio based biomarkers and methods of use thereof
JP2012527631A (ja) * 2009-05-22 2012-11-08 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ タキサン型化学療法剤用のインジケータとしてのｓｅｒ４７３でのａｋｔリン酸化反応
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
EP2810066B1 (en) * 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140357596A1 (en) * 2012-01-24 2014-12-04 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
JP5383836B2 (ja) 2012-02-03 2014-01-08 ファナック株式会社 検索ウィンドウを自動的に調整する機能を備えた画像処理装置
RU2702908C2 (ru) * 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
RU2557976C2 (ru) * 2013-05-07 2015-07-27 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ определения чувствительности клеток рака легкого к цисплатину на основании уровней экспрессии маркерных генов и набор для его осуществления
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US11371099B2 (en) 2015-11-30 2022-06-28 Mayo Foundation For Medical Education And Research HEATR1 as a marker for chemoresistance
PL3455631T3 (pl) * 2016-05-09 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Sposoby klasyfikowania pacjentów z nowotworem litym
EP3934699A4 (en) * 2019-03-04 2022-12-21 The Trustees of The University of Pennsylvania NEUROPROTECTIVE GENE THERAPY TARGETING THE AKT PATHWAY
RU2738167C1 (ru) * 2020-06-08 2020-12-09 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5998151A (en) * 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
PL204629B1 (pl) * 1999-06-25 2010-01-29 Genentech Inc Zastosowanie przeciwciała do wytwarzania leku do leczenia raka sutka, zastosowanie przeciwciała do leczenia raka jajnika, zastosowanie przeciwciała do wytwarzania leku do leczenia raka płuc i zastosowanie przeciwciała do leczenia raka okrężnicy, raka odbytnicy i raka jelita grubego i odbytu
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DK2189162T3 (da) 2000-11-09 2014-02-03 Oncolytics Biotech Inc Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
JP4246495B2 (ja) * 2001-02-27 2009-04-02 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート マイトゲン活性化蛋白質キナーゼリン酸化に基づくアルツハイマー病診断
US7049151B2 (en) * 2001-03-07 2006-05-23 Bio-Rad Laboratories, Inc. Assay system for simultaneous detection and measurement of multiple modified cellular proteins
JP2003189866A (ja) * 2001-12-26 2003-07-08 Sankyo Co Ltd 骨吸収抑制剤探索法
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
JP2007520995A (ja) 2003-01-08 2007-08-02 ブリストル−マイヤーズ　スクイブ　カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US7537906B2 (en) * 2003-01-29 2009-05-26 Nobuhiko Nomura Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone
JP2004229547A (ja) * 2003-01-29 2004-08-19 Nobuhiko Nomura アシル化ホモセリンラクトン阻害物質をスクリーニングする方法
EP1590487A2 (en) * 2003-02-06 2005-11-02 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
JP2004257783A (ja) * 2003-02-25 2004-09-16 Jgs:Kk 金属錯化合物抗癌剤に対する癌細胞の耐性の検査方法及び該耐性を低減させるための薬剤
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia

Also Published As

Publication number Publication date
BRPI0609096A2 (pt) 2010-02-17
US20070054330A1 (en) 2007-03-08
CN102854315A (zh) 2013-01-02
KR100962162B1 (ko) 2010-06-10
KR20070116641A (ko) 2007-12-10
RU2416096C2 (ru) 2011-04-10
IL185631A (en) 2011-12-29
US20100196931A1 (en) 2010-08-05
MX2007013973A (es) 2008-01-11
JP4847518B2 (ja) 2011-12-28
AU2006245962A1 (en) 2006-11-16
IL185631A0 (en) 2008-01-06
NO20074389L (no) 2007-12-06
EP1889066A1 (en) 2008-02-20
WO2006119980A1 (en) 2006-11-16
RU2007145514A (ru) 2009-06-20
AU2006245962B2 (en) 2011-11-03
AU2006245962B8 (en) 2011-12-08
JP2008538817A (ja) 2008-11-06
US7655414B2 (en) 2010-02-02
CA2605151A1 (en) 2006-11-16
JP2012021997A (ja) 2012-02-02

Similar Documents

Publication Publication Date Title
AR053272A1 (es) Determinacion de responsivos a la quimioterapia
UA116618C2 (uk) СКОНСТРУЙОВАНЕ НА ОСНОВІ ЦИСТЕЇНУ АНТИТІЛО ПРОТИ CD79b
NZ593226A (en) Gene expression markers (efnb2) for colorectal cancer prognosis
AR057323A1 (es) Metodo para la prediccion de la respuesta a un tratamiento
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
Zhou et al. Significance of TRIM29 and β-catenin expression in non-small-cell lung cancer
ES2527776T3 (es) Biomarcadores para predecir la sensibilidad de células a compuestos inmunomoduladores durante el tratamiento del linfoma no Hodgkin
DK1761651T3 (da) MNRA-forhold i urinsedimenter og/eller urin som en prognostisk og/eller teranostisk markør for prostatakræft
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
WO2008021290A9 (en) Organ-specific proteins and methods of their use
TW200716982A (en) Measuring thrombin activity in whole blood
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2008037700A3 (en) Methods for breast cancer prognosis
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
Choi et al. Lyso-globotriaosylceramide downregulates KCa3. 1 channel expression to inhibit collagen synthesis in fibroblasts
DE602005024964D1 (de) Verfahren zur beurteilung der malignität einer säuger-krebszelle
ATE505539T1 (de) Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
BR112012009527A2 (pt) dispositivo para detectar pelo menos um analito.
WO2009093856A3 (ko) 생물학적 의약품으로부터 마이코플라즈마를 검출하기 위한 ｐｃｒ 프라이머 세트 및 이를 포함하는 마이코플라즈마 검출용 키트
WO2009126804A3 (en) Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
WO2010030980A3 (en) Akt and clusterin as biomarkers of chemotherapeutic responsiveness
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal